Gabapentin Tablet, Film Coated
Product Images NDC 76282-406

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 76282-406). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

90t600 Ex As

Gabapentin Tablets, USP 600 mg film-coated oral tablets by Exelan Pharmaceuticals Inc. The label indicates 90 tablets per bottle, includes a barcode and a QR code, and states the product is prescription only. Storage instructions and manufacturer details for Ascent Pharmaceuticals, Inc., and Exelan Pharmaceuticals, Inc. are provided.*

FDA Label Image

90t600 Ex In

Gabapentin Tablets, USP 600 mg film-coated tablets label by Exelan Pharmaceuticals Inc. The label includes the dosage strength 600 mg and states 'Rx Only'. It indicates a package size of 90 tablets. The label notes instructions for pharmacists to dispense the medication guide separately and provides manufacturer information for InvaGen Pharmaceuticals, Inc. and Exelan Pharmaceuticals, Inc.*

FDA Label Image

90t800 Ex As

Label for Gabapentin Tablets, USP 800 mg film-coated oral tablets by Exelan Pharmaceuticals Inc. The label indicates a package of 90 tablets, includes storage instructions at 20°-25°C, and notes dispensing the medication guide separately. Manufactured by Ascent Pharmaceuticals, Inc.*

FDA Label Image

90t800 Ex In

Gabapentin Tablets USP 800 mg film-coated oral tablets, packaged with 90 tablets per container. Label indicates dispensing instructions, storage conditions at 20°-25°C, and manufacturer details including Exelan Pharmaceuticals Inc. and Invagen Pharmaceuticals. The NDC code is 76282-406-90.*

FDA Label Image

Gabapentin 05

A line graph showing mean pain score over 8 weeks comparing Placebo and Gabapentin (3600 mg/day). The x-axis shows weeks from baseline to 8, the y-axis shows mean pain score from 0 to 10. The graph marks a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Gabapentin 06

A line graph depicting mean pain scores over a 7-week period comparing placebo and gabapentin dosed at 1800 mg/day and 2400 mg/day. The x-axis shows weeks from baseline to week 7, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Gabapentin 07

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) at various dosages in two studies. Study 1 shows 12% responders for PBO and 29% for GBP 3600 mg. Study 2 shows 14% responders for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance levels (p < 0.01 and p < 0.001) are noted for gabapentin groups.*

FDA Label Image

Gabapentin 08

A scatter plot chart showing difference percentages by daily dose (mg) for three studies labeled a, b, and c. The x-axis represents daily doses ranging from 600 to 1800 mg, while the y-axis shows difference percentages from 2% to 22%. Data points for each study are marked with distinct symbols at various dose levels.*

FDA Label Image

Equation 1 (Image 01)

A formula showing creatinine clearance (CLCr) calculation based on age, weight, serum creatinine, and a factor for female patients. The formula is presented as a ratio combining these variables mathematically.*

FDA Label Image

Structure

Chemical structure diagram of gabapentin, showing a cyclohexane ring bonded to amino (CH2NH2) and carboxyl (CH2CO2H) functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.